Physician profile
John W Hogan
NPI 1114074838
$353,989.47
in general payments reported to CMS, 2019-2025
6 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134K · 2020: $44K · 2021: $19K · 2022: $35K · 2023: $42K · 2024: $51K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Travel and Lodging: $14K · Food and Beverage: $5,308 · Consulting Fee: $4,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,315.25 |
| Travel and Lodging | $14,291.14 |
| Food and Beverage | $5,308.35 |
| Consulting Fee | $4,680.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $296,910.56 | 2019-2025 | Biktarvy, Epclusa, Sunlenca |
| Merck Sharp & Dohme LLC | $24,278.11 | 2022-2025 | Pifeltro |
| Viiv Healthcare Company | $23,293.58 | 2019-2022 | |
| Janssen Products, LP | $8,582.50 | 2019-2022 | |
| Theratechnologies INC. | $824.14 | 2023-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Alnylam Pharmaceuticals INC. | $100.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.